Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech’s Phase III colon cancer trial fails primary endpoint
Genentech has reported that a Phase III study of Avastin plus chemotherapy following surgery in patients with early-stage colon cancer did not meet its primary endpoint of reducing
Genentech has reported that a Phase III study of Avastin plus chemotherapy following surgery in patients with early-stage colon cancer did not meet its primary endpoint of reducing
Transave has completed patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace in non-cystic fibrosis bronchiectasis patients. The double-blind, placebo-controlled study is designed
In this role, Mr Nicklas will oversee sales, marketing and managed care efforts for BTA’s products. Prior to joining Biovail, Mr Nicklas was senior director of epilepsy marketing
Neoteric’s products will be integrated into Haemonetics’s patient division for marketing and sales. The company’s operations will remain in Vancouver, British Columbia and the UK. Natixis Bleichroeder acted
The data show that RGB-286638 demonstrates in vivo activity in several preclinical models of multiple myeloma. The compound also induces cell death in multiple myeloma cells independent from
Patient Safety Technologies, a developer, manufacturer and provider of patient safety products and services, has reported a net loss of $630,000, or $0.05 per share, for the fourth
Quarterly Snapshot Revenues decreased 12% Adjusted EPS declined 15% Generated record free cash flow of more than $310 million Significant new products launched to address customer needs for
Business Outlook For the fiscal 2009, the company anticipates total revenue to be in the range of $164 million to $174 million, loss per share in the range
2009 Guidance Update Looking ahead for fiscal 2009, Amgen projects revenue outlook to a range of $14.4 billion to $14.8 billion from its prior estimate of $14.8 billion
“We are very pleased to have ELITech UK become our exclusive UK distributor. Their demonstrated expertise in this market and knowledge of our customer base in the UK